Concert Pharmaceuticals Inc (CNCE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Concert Pharmaceuticals Inc (CNCE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9797
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Concert Pharmaceuticals Inc (Concert Pharmaceuticals) is a clinical stage biotechnology company which discovers and develops small molecule drugs. The company develops its products using its deuterated chemical entity (DCE) platform to develop novel therapeutics for autoimmune and inflammatory diseases, pulmonary diseases, and disorders of central nervous system (CNS). Its product pipeline includes CTP-543 (deuterated ruxolitinib) for alopecia areata; AVP-786 (deuterated dextromethorphan) indicated for alzheimer’s agitation, major depressive disorder and residual schizophrenia; CTP-730 (deuterated apremilast) for inflammatory diseases; CTP-692, a selective DCE modified analog of the endogenous amino acid, D-serine for Schizophrenia, and JZP-386 (deuterated sodium-oxybate) for narcolepsy. It employs its deuterated compounds to reduce the extent of metabolism in the wall of the intestines and in the liver. Concert Pharmaceuticals is headquartered in Lexington, Massachusetts, the US.

Concert Pharmaceuticals Inc (CNCE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Concert Pharma Raises USD30 Million in Venture Debt Financing 10
Partnerships 11
Concert Pharma Enters Into Co-Development Agreement With Celgene 11
Concert Pharma Enters Into Co-Development Agreement With Fast Forward For C-21191 12
Licensing Agreements 13
Processa Pharma Enters into Licensing Agreement with Concert Pharma 13
Processa Pharma Enters into Option Licensing Agreement with Concert Pharma 14
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 15
Concert Pharma Enters Into Licensing Agreement With AVANIR Pharma For Neurology And Psychiatry Drugs 17
Equity Offering 19
Concert Pharma Files Shelf Registration Statement with SEC to Raise USD250 Million 19
Concert Pharma Raises USD50 Million in Public Offering of Shares 20
Concert Pharma Completes Underwriters Exercise Of Over-Allotment Option Of IPO For US$93 Million 22
Asset Transactions 24
Vertex Pharma Acquires CTP-656 from Concert Pharma 24
Concert Pharmaceuticals Inc – Key Competitors 26
Concert Pharmaceuticals Inc – Key Employees 27
Concert Pharmaceuticals Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Nov 01, 2018: Concert Pharmaceuticals reports third quarter 2018 financial results and provides company update 29
Aug 02, 2018: Concert Pharmaceuticals reports second quarter 2018 financial results and provides company update 30
May 03, 2018: Concert Pharmaceuticals Reports First Quarter 2018 Financial Results 31
Mar 01, 2018: Concert Pharmaceuticals Reports Year Ended 2017 Financial Results 33
Nov 09, 2017: Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update 34
Aug 08, 2017: Concert Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Company Update 35
May 02, 2017: Concert Pharmaceuticals Reports First Quarter 2017 Financial Results 37
Mar 06, 2017: Concert Pharmaceuticals Reports Year Ended 2016 Financial Results 38
Corporate Communications 40
Dec 18, 2017: Concert Pharmaceuticals Announces the Appointment of Marc Becker as Chief Financial Officer 40
Dec 13, 2017: Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index 41
May 30, 2017: Concert Pharmaceuticals Announces Departure of Chief Financial Officer, Ryan Daws 42
Product News 43
02/28/2018: Concert Pharmaceuticals Announces Advancement of Novel Drug Candidate in Schizophrenia 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Concert Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Concert Pharma Raises USD30 Million in Venture Debt Financing 10
Concert Pharma Enters Into Co-Development Agreement With Celgene 11
Concert Pharma Enters Into Co-Development Agreement With Fast Forward For C-21191 12
Processa Pharma Enters into Licensing Agreement with Concert Pharma 13
Processa Pharma Enters into Option Licensing Agreement with Concert Pharma 14
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 15
Concert Pharma Enters Into Licensing Agreement With AVANIR Pharma For Neurology And Psychiatry Drugs 17
Concert Pharma Files Shelf Registration Statement with SEC to Raise USD250 Million 19
Concert Pharma Raises USD50 Million in Public Offering of Shares 20
Concert Pharma Completes Underwriters Exercise Of Over-Allotment Option Of IPO For US$93 Million 22
Vertex Pharma Acquires CTP-656 from Concert Pharma 24
Concert Pharmaceuticals Inc, Key Competitors 26
Concert Pharmaceuticals Inc, Key Employees 27
Concert Pharmaceuticals Inc, Subsidiaries 28

List of Figures
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Concert Pharmaceuticals Inc (CNCE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Landeskreditbank Baden-Wuerttemberg-Foerderbank:企業の戦略・SWOT・財務分析
    Landeskreditbank Baden-Wuerttemberg-Foerderbank - Strategy, SWOT and Corporate Finance Report Summary Landeskreditbank Baden-Wuerttemberg-Foerderbank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • University of California San Diego:医療機器:M&Aディール及び事業提携情報
    Summary University of California San Diego (UCSD), a subsidiary of University of California, is a public research university that offers education and research with a portfolio of undergraduate, graduate, postdoctoral and professional schools. It offers courses in various fields including arts and h …
  • Saline Water Conversion Corp:企業の戦略的SWOT分析
    Saline Water Conversion Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Philippine National Bank:企業の戦略・SWOT・財務情報
    Philippine National Bank - Strategy, SWOT and Corporate Finance Report Summary Philippine National Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • JALUX Inc:企業の戦略・SWOT・財務情報
    JALUX Inc - Strategy, SWOT and Corporate Finance Report Summary JALUX Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Danieli & C. Officine Meccaniche SpA:企業の戦略・SWOT・財務情報
    Danieli & C. Officine Meccaniche SpA - Strategy, SWOT and Corporate Finance Report Summary Danieli & C. Officine Meccaniche SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Innate Pharma SA (IPH):企業の財務・戦略的SWOT分析
    Summary Innate Pharma SA (Innate Pharma) is a healthcare products provider that develops immunopharmacology and antibody technology products. The company carries out the discovery and development of therapeutic antibodies for the treatment of cancer and inflammatory diseases. It develops new monoclo …
  • Morinaga & Co. Ltd.:企業の戦略・SWOT・財務情報
    Morinaga & Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Morinaga & Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Satrec Initiative Co., Ltd.:企業の戦略・SWOT・財務分析
    Satrec Initiative Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Satrec Initiative Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Avon Rubber Plc (AVON):企業の財務・戦略的SWOT分析
    Avon Rubber Plc (AVON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Advanced Accelerator Applications SA:医療機器:M&Aディール及び事業提携情報
    Summary Advanced Accelerator Applications SA (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The company’s lead product candidate comprises Lutathera, NETSPOT, SOMAKIT TOC, Gluscan, Gluscan 500, Barnas …
  • SVOGL Oil Gas and Energy Ltd:企業の戦略的SWOT分析
    SVOGL Oil Gas and Energy Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Abion Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Abion Inc (Abion) is a biopharmaceutical company that conducts research activities to develop biopharmaceutical drugs and companion diagnostic systems for the treatment of incurable diseases. The company offers preclinical phase products such as ABN101, ABN301, ABN302, ABN401, and others. It …
  • Tuas Power Ltd:企業の戦略的SWOT分析
    Tuas Power Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Kyobo Life Insurance Co Ltd:企業の戦略・SWOT・財務情報
    Kyobo Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Kyobo Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • ENERQOS SpA:電力:M&Aディール及び事業提携情報
    Summary Enerqos SpA (Enerqos), a subsidiary of Climate Change Capital Private Equity LP, is an energy service company that offer solutions to improve energy efficiency. The company operates in the planning, management, financing and monitoring of projects in the renewable energy sector. It implement …
  • China Shineway Pharmaceutical Group Ltd (2877):企業の財務・戦略的SWOT分析
    Summary China Shineway Pharmaceutical Group Ltd (China Shineway) is a pharmaceutical company that offers development, manufacture and sales of Chinese medicines. The company’s products comprise shenmai injection, qingkailing injection, huangqi injection, shuxiening injection, wufu xinnaoqing soft ca …
  • F-Secure Oyj (FSC1V):企業の財務・戦略的SWOT分析
    F-Secure Oyj (FSC1V) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • PT Central Proteina Prima Tbk (CPRO):企業の財務・戦略的SWOT分析
    PT Central Proteina Prima Tbk (CPRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • CryoPort Inc (CYRX):企業の財務・戦略的SWOT分析
    CryoPort Inc (CYRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆